CardieX (ASX:CDX) formally lodged its application with the Therapeutic Goods Administration for the inclusion of the CONNEQT Pulse device in the government authority's register, according to a Tuesday filing with the Australian bourse.

The US Food and Drug Administration-approved device provides arterial health insights that are useful in managing cardiovascular disease, the filing said.

The registration process is expected to take three to six months, per the filing.

CardieX's shares rose 8% in recent trade.

Price (AUD): $0.06, Change: $+0.0040, Percent Change: +7.69%